

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

April 2024

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a large, stylized graphic of white wavy lines on a grey background.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 April 2024.....	3
Section H changes to Part II	4
Index.....	8

Summary of decisions

EFFECTIVE 1 APRIL 2024

- Amoxicillin (Alphamox) cap 250 mg and 500 mg – delay delist date
- Amoxicillin (Miro-Amoxicillin) cap 250 mg and 500 mg – delay PSS start date
- Aripiprazole (Abilify Maintena) inj 300 mg vial and 400 mg vial
– amended restriction criteria
- Dosulepin [Dothiepin] hydrochloride (Dosulepin Mylan) cap 25 mg – to be delisted 1 October 2024
- Eplerenone (Inspra) tab 50 mg, Pharmacode 2555069 – to be delisted 1 July 2024
- Letrozole (Letrole) tab 2.5 mg, Pharmacode 2474425 – to be delisted 1 July 2024
- Meningococcal (A, C, Y AND W-135) conjugate vaccine (MenQuadfi)
– amended restriction criteria
- Meningococcal B multicomponent vaccine (Bexsero) – amended restriction criteria
- Multivitamin renal (Clinicians Renal Vit) cap – price increase
- Olanzapine (Zyprexa Relprev) inj 210 mg vial, 300 mg vial and 405 mg vial
– amended restriction criteria
- Oral feed 1.5 kcal/ml liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can (Ensure Plus (Vanilla)) and liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, carton (Ensure Plus (Banana, Chocolate, Fruit of the Forest and Vanilla)) – price increase
- Oral feed 2 kcal/ml (Two Cal HN) liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle – price increase
- Prazosin (Prazosin Mylan) cab 1 mg, 2 mg and 5 mg – new listing
- Testosterone (Testogel) gel (transdermal) 16.2 mg per g, 88 g – new listing and addition of PSS
- Testosterone undecanoate cap 40 mg – new listing
- Testosterone undecanoate (Andriol Testocaps) cap 40 mg – to be delisted 1 April 2024
- Tobramycin (Tobramycin (Viatris)) inj 40 mg per ml, 2 ml vial – amended brand name
- Warfarin sodium (Marevan) tab 1 mg, 3 mg and 5 mg – price increase

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 April 2024

ALIMENTARY TRACT AND METABOLISM

26	MULTIVITAMIN RENAL (↑ price) → Cap	7.28	30	Clinicians Renal Vit
----	---------------------------------------------	------	----	----------------------

BLOOD AND BLOOD FORMING ORGANS

37	WARFARIN SODIUM (↑ price)			
	Tab 1 mg.....	7.50	100	Marevan
	Tab 3 mg.....	12.00	100	Marevan
	Tab 5 mg.....	13.50	100	Marevan

CARDIOVASCULAR SYSTEM

46	PRAZOSIN (new listing)			
	Cap 1 mg	15.40	100	Prazosin Mylan
	Cap 2 mg	15.58	100	Prazosin Mylan
	Cap 5 mg	23.32	100	Prazosin Mylan

51	EPLERENONE (delisting) → Tab 50 mg – 5% DV Jun-22 to 2024	25.00	30	Inspira
	Note – Inspira tab 50 mg, Pharmacode 2555069, to be delisted from 1 July 2024			

HORMONE PREPARATIONS

79	TESTOSTERONE (new listing and addition of PSS) Gel (transdermal) 16.2 mg per g – 5% DV Jul-24 to 2027.....	52.00	88 g	Testogel
----	---------------------------------------------------------------------------------------------------------------	-------	------	----------

79	TESTOSTERONE UNDECANOATE (new listing) → Cap 40 mg – Restricted: For continuation only Note – Andriol Testocaps cap 40 mg to be delisted from 1 April 2024			
----	------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--

INFECTIONS

89	TOBRAMYCIN (amended brand name) → Inj 40 mg per ml, 2 ml vial – 5% DV Jul-23 to 2024.....	18.50	5	Tobramycin (Viatrix)
----	----------------------------------------------------------------------------------------------	-------	---	----------------------

93	AMOXICILLIN (delay PSS start date and delist date) Cap 250 mg – 5% DV Sep-24 May-24 to 2025.....	27.50	500	Miro-Amoxicillin
	Cap 500 mg – 5% DV Aug-24 May-24 to 2025.....	41.00	500	Miro-Amoxicillin
	Note – Alphamox cap 250 mg and 500 mg to be delisted from 1 May 2024. Alphamox cap 250 mg to be delisted from 1 September 2024 and cap 500 mg to be delisted from 1 August 2024			

NERVOUS SYSTEM

127	DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE (delisting) → Cap 25 mg	7.83	50	Dosulepin Mylan
	Note – Dosulepin Mylan cap 25 mg to be delisted from 1 October 2024			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2024 (continued)

134	ARIPIPRAZOLE (amended restriction criteria)			
	→ Inj 300 mg vial.....	273.56	1	Abilify Maintena
	→ Inj 400 mg vial.....	341.96	1	Abilify Maintena

Initiation

Re-assessment required after 12 months

Either Both:

1 Both

1.1 Patient has a current Special Authority approval for olanzapine depot injection, risperidone depot injection or paliperidone depot injection; and

2—Either:

1.2 ~~2.1~~ Patient has tried but has experienced an inadequate response to, or intolerable side effects from, prior therapy with olanzapine depot injection, risperidone depot injection or paliperidone depot injection; or

2 2.2 Patient has been unable to access olanzapine depot injection due to supply issues with olanzapine depot injection, or otherwise would have been initiated on olanzapine depot injection but has been unable to due to supply issues with olanzapine depot injection. (**see Note below for the olanzapine Special Authority criteria for new olanzapine depot injection patients prior to 1 April 2024**)

Note: The Olanzapine depot injection Special Authority criteria that apply to criterion 2 in this Aripiprazole Special Authority application are as follows:

1 The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or

2 All of the following:

2.1 The patient has schizophrenia; and

2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and

2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of aripiprazole depot injection has been associated with fewer days of intensive intervention than prior to the initiation of an atypical antipsychotic depot injection.

135	OLANZAPINE (amended restriction criteria)			
	→ Inj 210 mg vial.....	252.00	1	Zyprexa Relprev
	→ Inj 300 mg vial.....	414.00	1	Zyprexa Relprev
	→ Inj 405 mg vial.....	504.00	1	Zyprexa Relprev

Initiation

Re-assessment required after 12 months

Either:

1—The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or

2—All of the following:

2.1 The patient has schizophrenia; and

2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and

2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2024 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

167	LETROZOLE (delisting) Tab 2.5 mg – 5% DV Jan-22 to 2024	5.84	30	Letrole
Note – Letrole tab 2.5 mg, Pharmacode 2474425, to be delisted from 1 July 2024				

SPECIAL FOODS

280	ORAL FEED 2 KCAL/ML (↑ price) → Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle	2.34	200 ml	Two Cal HN
289	ORAL FEED 1.5 KCAL/ML (↑ price) → Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can	1.65	237 ml	Ensure Plus (Vanilla)
	→ Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, carton	1.56	200 ml	Ensure Plus (Banana) Ensure Plus (Chocolate) Ensure Plus (Fruit of the Forest) Ensure Plus (Vanilla)

VACCINES

291	MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE (amended restriction criteria) → Inj 10 mcg of each meningococcal polysaccharide conjugated to a total of approximately 55 mcg of tetanus toxoid carrier per 0.5 ml vial	0.00	1	MenQuadfi
-----	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------	---	-----------

Initiation

Either:

1 Any of the following:

- 1.1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
- 1.2 One dose for close contacts of meningococcal cases of any group; or
- 1.3 One dose for person who has previously had meningococcal disease of any group; or
- 1.4 A maximum of two doses for bone marrow transplant patients; or
- 1.5 A maximum of two doses for person pre and post-immunosuppression*; or

2 Both:

2.1 Person is aged between 13 and 25 years, inclusive; and

2.2 **Either:**

2.2.1 One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons; **or**

2.2.2 **One dose for individuals who turn 13 years of age while living in boarding school hostels.**

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2024 (continued)

292	MENINGOCOCCAL B MULTICOMPONENT VACCINE (amended restriction criteria)			
	→ Inj 175 mcg per 0.5 ml prefilled syringe	0.00	1	Bexsero
			10	Bexsero

Initiation – Primary immunisation for children up to 12 months of age

Therapy limited to 3 doses

Either:

- 1 Three doses for children up to 12 months of age (inclusive) for primary immunisation; or
- 2 Up to three doses (dependent on age at first dose) for a catch-up programme for children from 13 months to 59 months of age (inclusive) for primary immunisation, from 1 March 2023 to 31 August 2025.

Initiation – Person is one year of age or over

Any of the following:

- 1 up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
- 2 up to two doses for close contacts of meningococcal cases of any group; or
- 3 up to two doses for person who has previously had meningococcal disease of any group; or
- 4 up to two doses for bone marrow transplant patients; or
- 5 up to two doses for person pre- and post-immunosuppression*

Initiation – Person is aged between 13 and 25 years (inclusive)

Therapy limited to 2 doses

Both:

- 1 Person is aged between 13 and 25 years (inclusive); and

2 Either:

- 2.1 Two doses for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, **Youth Justice residences**, or prisons; or
- 2.2 Two doses for individuals who **turn 13 years of age while** ~~are currently~~ living in boarding school hostels, ~~tertiary education halls of residence, military barracks, or prisons, from 1 March 2023 to 28 February 2024.~~

Note: *Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Index

Pharmaceuticals and brands

A		
Abilify Maintena	5	
AMOXICILLIN	4	
ARIPIPIRAZOLE.....	5	
B		
Bexsero	7	
C		
Clinicians Renal Vit.....	4	
D		
DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE	4	
Dosulepin Mylan	4	
DOTHIEPIN	4	
E		
Ensure Plus (Banana).....	6	
Ensure Plus (Chocolate).....	6	
Ensure Plus (Fruit of the Forest).....	6	
Ensure Plus (Vanilla)	6	
EPLERENONE	4	
I		
Inspra	4	
L		
Letrole	6	
LETROZOLE	6	
M		
Marevan.....	4	
		MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE
		6
		MENINGOCOCCAL B MULTICOMPONENT VACCINE
		7
		MenQuadfi
		6
		Miro-Amoxicillin
		4
		MULTIVITAMIN RENAL.....
		4
		O
		OLANZAPINE.....
		5
		ORAL FEED 1.5 KCAL/ML
		6
		ORAL FEED 2 KCAL/ML
		6
		P
		PRAZOSIN
		4
		Prazosin Mylan
		4
		T
		Testogel.....
		4
		TESTOSTERONE
		4
		TESTOSTERONE UNDECANOATE
		4
		TOBRAMYCIN
		4
		Tobramycin (Viatris).....
		4
		Two Cal HN.....
		6
		W
		WARFARIN SODIUM
		4
		Z
		Zyprexa Relprevv
		5

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

